BACKGROUND: Ovarian cancer has the highest mortality rate of all gynaecologic cancers. Faced with poor prognoses, stressful treatment effects and a high likelihood of recurrence, survivors must confront significant physical and psychological morbidities that negatively impact health-related quality of life. Frequently reported side effects include cancer-related fatigue, peripheral neuropathy, and psychological distress. Exercise and cognitive behavioral therapy interventions have counteracted such adverse effects in other cancer populations. OBJECTIVE: To investigate the feasibility and benefits of a 24-week home-based exercise intervention, coordinated with 12 weeks of cognitive behavioral therapy (two sessions per month), developed for two types of patients diagnosed with epithelial ovarian cancer: 1) those undergoing primary treatment with adjuvant chemotherapy after primary surgery; 2) those on surveillance after completing treatment within the last 2 years. METHODS:Participants were recruited from the Gynaecologic Oncology Clinic. Eligible participants completed baseline assessments and were provided with home-based exercise equipment. Cognitive behavioral therapy was provided every other week for patients via telephone. Assessments were completed at baseline (T1), 3 months (T2) and 6 months (T3). RESULTS: 19 of the 46 eligible patients approached were enrolled, with 7 patients in the treatment group and 12 in the surveillance group. There was a significant within group increase in peak VO2 from baseline to 6 months: F(2,16) = 5.531, p = 0.015, partial η2 = 0.409. CONCLUSION: The combined 6-month exercise-cognitive behavioral therapy intervention was associated with significant increases in aerobic fitness in epithelial ovarian cancer patients assessed. These improvements were similar regardless of whether the patient was receiving chemotherapy or under surveillance.
RCT Entities:
BACKGROUND:Ovarian cancer has the highest mortality rate of all gynaecologic cancers. Faced with poor prognoses, stressful treatment effects and a high likelihood of recurrence, survivors must confront significant physical and psychological morbidities that negatively impact health-related quality of life. Frequently reported side effects include cancer-related fatigue, peripheral neuropathy, and psychological distress. Exercise and cognitive behavioral therapy interventions have counteracted such adverse effects in other cancer populations. OBJECTIVE: To investigate the feasibility and benefits of a 24-week home-based exercise intervention, coordinated with 12 weeks of cognitive behavioral therapy (two sessions per month), developed for two types of patients diagnosed with epithelial ovarian cancer: 1) those undergoing primary treatment with adjuvant chemotherapy after primary surgery; 2) those on surveillance after completing treatment within the last 2 years. METHODS:Participants were recruited from the Gynaecologic Oncology Clinic. Eligible participants completed baseline assessments and were provided with home-based exercise equipment. Cognitive behavioral therapy was provided every other week for patients via telephone. Assessments were completed at baseline (T1), 3 months (T2) and 6 months (T3). RESULTS: 19 of the 46 eligible patients approached were enrolled, with 7 patients in the treatment group and 12 in the surveillance group. There was a significant within group increase in peak VO2 from baseline to 6 months: F(2,16) = 5.531, p = 0.015, partial η2 = 0.409. CONCLUSION: The combined 6-month exercise-cognitive behavioral therapy intervention was associated with significant increases in aerobic fitness in epithelial ovarian cancerpatients assessed. These improvements were similar regardless of whether the patient was receiving chemotherapy or under surveillance.
Authors: Bernardine M Pinto; Georita M Frierson; Carolyn Rabin; Joseph J Trunzo; Bess H Marcus Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: Victoria Mock; Constantine Frangakis; Nancy E Davidson; Mary E Ropka; Mary Pickett; Barbara Poniatowski; Kerry J Stewart; Lane Cameron; Kristin Zawacki; Laura J Podewils; Gary Cohen; Ruth McCorkle Journal: Psychooncology Date: 2005-06 Impact factor: 3.894
Authors: C M Donnelly; A Lowe-Strong; J P Rankin; A Campbell; J M Blaney; J H Gracey Journal: Support Care Cancer Date: 2013-01-16 Impact factor: 3.603
Authors: Irene Korstjens; Anne M May; Ellen van Weert; Ilse Mesters; Frans Tan; Wynand J G Ros; Josette E H M Hoekstra-Weebers; Cees P van der Schans; Bart van den Borne Journal: Psychosom Med Date: 2008-05 Impact factor: 4.312
Authors: Tina R Norton; Sharon L Manne; Stephen Rubin; John Carlson; Enrique Hernandez; Mitchell I Edelson; Norman Rosenblum; David Warshal; Cynthia Bergman Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Paul B Jacobsen; Jennifer Le-Rademacher; Heather Jim; Karen Syrjala; John R Wingard; Brent Logan; Juan Wu; Navneet S Majhail; William Wood; J Douglas Rizzo; Nancy L Geller; Carrie Kitko; Edward Faber; Muneer H Abidi; Susan Slater; Mary M Horowitz; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2014-06-06 Impact factor: 5.742
Authors: Brenda Cartmel; Meghan Hughes; Elizabeth A Ercolano; Linda Gottlieb; Fangyong Li; Yang Zhou; Maura Harrigan; Jennifer A Ligibel; Vivian E von Gruenigen; Radhika Gogoi; Peter E Schwartz; Harvey A Risch; Lingeng Lu; Melinda L Irwin Journal: Gynecol Oncol Date: 2021-03-26 Impact factor: 5.482
Authors: Mette-Marie Dybeck; Lis Adamsen; Victor Sørensen; Christian Lillelund; Tom Møller; Christina Andersen Journal: Eur J Cancer Care (Engl) Date: 2022-05-12 Impact factor: 2.328
Authors: Ellen M Kinner; Jessica S Armer; Bonnie A McGregor; Jennifer Duffecy; Susan Leighton; Marya E Corden; Janine Gauthier Mullady; Frank J Penedo; Susan K Lutgendorf Journal: JMIR Cancer Date: 2018-01-15